Synribo (Omacetaxine Mepesuccinate) for Myeloproliferative Neoplasms

Overview
Synribo is approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic or accelerated-phase chronic myeloid leukemia (CML) who have developed resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs). It is generally prescribed when other treatments are ineffective or not tolerated. Synribo is also known by its drug name, omacetaxine mepesuccinate.

Synribo works by inhibiting protein synthesis, which disrupts the growth of cancer cells. It is thought to reduce the excessive production of abnormal blood cells that characterizes CML.

How do I take it?
Prescribing information states that Synribo is administered as a subcutaneous (under the skin) injection. For initial induction, it is given twice daily for 14 consecutive days within a 28-day cycle. After induction, a maintenance dose is given twice daily for seven consecutive days of a 28-day cycle. This treatment should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Synribo include thrombocytopenia (low platelet count), anemia, neutropenia (low neutrophil count), diarrhea, nausea, fatigue, weakness, injection site reactions, fever, infections, and lymphopenia (low lymphocyte count).

Rare but serious side effects may include severe and potentially fatal myelosuppression (decreased bone marrow activity), significant bleeding (including cerebral hemorrhage and severe gastrointestinal bleeding), hyperglycemia (high blood sugar) that can result in hyperosmolar nonketotic hyperglycemia (a severe blood sugar imbalance), and risks to fetal development if taken during pregnancy.

For more information about this treatment, visit:

Synribo — Drugs.com